© 1997 American Heart Association, Inc.
Articles |
No Evidence of Linkage Between Familial Combined Hyperlipidemia and Genes Encoding Lipolytic Enzymes in Finnish Families
From the National Public Health Institute, Department of Human Molecular Genetics (P.P., M.P., A.-C.S., L.P.); the Department of Medicine, University of Helsinki (K.V.K.P., M.-R.T., L.S., A.-T.L.); the National Public Health Institute, Department of Biochemistry (M.A., S.M.-R., S.E., C.E.); and the Department of Medicine, University of Turku (I.N., J.S.A.V.), Finland, part of the EUFAM group.
Abstract Familial combined hyperlipidemia (FCHL) is characterized by different lipid phenotypes (IIa, IIb, IV) and elevated apolipoprotein B (apo B) levels in affected family members. Despite intensive research, the genes involved in the expression of this complex disorder have not been identified, probably because of problems associated with phenotype definition, unknown mode of inheritance, and most probably genetic heterogeneity. To explore the genetics of FCHL in the genetically homogeneous Finnish population, we collected 14 well-documented Finnish pedigrees with premature coronary heart disease and FCHL-like dyslipidemia. The lipolytic enzymes lipoprotein lipase (LPL), hepatic lipase (HL), and hormone-sensitive lipase (HSL) were selected as initial candidate genes because of their central roles in apo B and triglyceride metabolism. On the basis of the pedigree structures, a dominant mode of inheritance was adopted for linkage analyses, and serum total cholesterol and/or triglyceride levels exceeding the 90th percentile level were set as diagnostic criteria (criterion 1). In pairwise linkage analyses with intragenic markers, no evidence for linkage was found. Instead, the significantly negative LOD scores suggested exclusion of all three loci for single major gene effect. LOD scores were -14.63, -5.03, and -5.70 for the three LPL polymorphisms (
=0.00); -9.40, -6.30, and -4.74 for the three HL polymorphisms (=0.00); and -15.29 for the HSL polymorphism (=0.00). The results were very similar when apo B levels over the 90th percentile were used as criteria for affected status (criterion 2). Also, when linkage calculations were carried out using an intermediate or recessive mode of inheritance, the results of pairwise linkage analysis remained negative. Furthermore, when haplotypes were constructed from multiple polymorphisms of the LPL and HL genes, no segregation with the FCHL phenotype could be observed in the 14 Finnish families. Data obtained by the affected sib-pair method supported these findings, suggesting that the LPL, HL, or HSL genes do not represent major loci influencing the expression of the FCHL phenotype.
Key Words: familial combined hyperlipidemia • lipolytic enzymes • linkage analysis • genetics • complex disease
This article has been cited by other articles:
 |
|
 |
|
  C. L. Plaisier, M. Kyttala, D. Weissglas-Volkov, J. S. Sinsheimer, A. Huertas-Vazquez, L. Riba, S. Ramirez-Jimenez, T. W.A. de Bruin, T. Tusie-Luna, B. E. Aouizerat, et al. Galanin Preproprotein Is Associated With Elevated Plasma Triglycerides Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 147 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. van der Vleuten, A. Isaacs, A. Hijmans, C. M. van Duijn, A. F. H. Stalenhoef, and J. de Graaf The involvement of upstream stimulatory factor 1 in Dutch patients with familial combined hyperlipidemia J. Lipid Res., January 1, 2007; 48(1): 193 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Soro, M. Jauhiainen, C. Ehnholm, and M.-R. Taskinen Determinants of low HDL levels in familial combined hyperlipidemia J. Lipid Res., August 1, 2003; 44(8): 1536 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vakkilainen, M. Jauhiainen, K. Ylitalo, I. O. Nuotio, J. S. A. Viikari, C. Ehnholm, and M.-R. Taskinen LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins J. Lipid Res., April 1, 2002; 43(4): 598 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Meijssen, R. J. Derksen, S. Bilecen, D. W. Erkelens, and M. C. Cabezas In Vivo Modulation of Plasma Free Fatty Acids in Patients with Familial Combined Hyperlipidemia Using Lipid-Lowering Medication J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1576 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Stumvoll, H. G. Wahl, S. Jacob, A. Rettig, F. Machicao, and H. Haring Two novel prevalent polymorphisms in the hormone-sensitive lipase gene have no effect on insulin sensitivity of lipolysis and glucose disposal J. Lipid Res., November 1, 2001; 42(11): 1782 - 1788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Coon, R. H. Myers, I. B. Borecki, D. K. Arnett, S. C. Hunt, M. A. Province, L. Djousse, and M. F. Leppert Replication of Linkage of Familial Combined Hyperlipidemia to Chromosome 1q With Additional Heterogeneous Effect of Apolipoprotein A-I/C-III/A-IV Locus : The NHLBI Family Heart Study Arterioscler Thromb Vasc Biol, October 1, 2000; 20(10): 2275 - 2280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Friedlander, P. J. Talmud, K. L. Edwards, S. E. Humphries, and M. A. Austin Sib-pair linkage analysis of longitudinal changes in lipoprotein risk factors and lipase genes in women twins J. Lipid Res., August 1, 2000; 41(8): 1302 - 1309. [Abstract] [Full Text]
|
|
|
|
|
|
J. Pihlajamaki, L. Karjalainen, P. Karhapaa, I. Vauhkonen, M.-R. Taskinen, S. S. Deeb, and M. Laakso G-250A Substitution in Promoter of Hepatic Lipase Gene Is Associated With Dyslipidemia and Insulin Resistance in Healthy Control Subjects and in Members of Families With Familial Combined Hyperlipidemia Arterioscler Thromb Vasc Biol, July 1, 2000; 20(7): 1789 - 1795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pihlajamaki, L. Karjalainen, P. Karhapaa, I. Vauhkonen, and M. Laakso Impaired Free Fatty Acid Suppression During Hyperinsulinemia Is a Characteristic Finding in Familial Combined Hyperlipidemia, but Insulin Resistance Is Observed Only in Hypertriglyceridemic Patients Arterioscler Thromb Vasc Biol, January 1, 2000; 20(1): 164 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Aouizerat, H. Allayee, R. M. Cantor, G. M. Dallinga-Thie, C. D. Lanning, T. W. A. de Bruin, A. J. Lusis, and J. I. Rotter Linkage of a Candidate Gene Locus to Familial Combined Hyperlipidemia : Lecithin:Cholesterol Acyltransferase on 16q Arterioscler Thromb Vasc Biol, November 1, 1999; 19(11): 2730 - 2736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Groenendijk, R. M. Cantor, N. H. H. C. Blom, J. I. Rotter, T. W. A. de Bruin, and G. M. Dallinga-Thie Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia J. Lipid Res., June 1, 1999; 40(6): 1036 - 1044. [Abstract] [Full Text]
|
|
|
|
 |
|
 O.-P. Pitkanen, P. Nuutila, O. T. Raitakari, K. Porkka, H. Iida, I. Nuotio, T. Ronnemaa, J. Viikari, M.-R. Taskinen, C. Ehnholm, et al. Coronary Flow Reserve in Young Men With Familial Combined Hyperlipidemia Circulation, April 6, 1999; 99(13): 1678 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Tahvanainen, P. Pajukanta, K. Porkka, S. Nieminen, L. Ikavalko, I. Nuotio, M.-R. Taskinen, L. Peltonen, and C. Ehnholm Haplotypes of the ApoA-I/C-III/A-IV Gene Cluster and Familial Combined Hyperlipidemia Arterioscler Thromb Vasc Biol, November 1, 1998; 18(11): 1810 - 1817. [Abstract] [Full Text] [PDF]
|
|